Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

259.06
+4.301.69%
Volume:372.69K
Turnover:96.04M
Market Cap:457.85B
PE:127.61
High:259.12
Open:257.16
Low:256.49
Close:254.76
52wk High:261.64
52wk Low:184.63
Shares:1.77B
Float Shares:1.76B
Volume Ratio:0.97
T/O Rate:0.02%
Dividend:6.74
Dividend Rate:2.60%
EPS(TTM):2.03
EPS(LYR):2.36
ROE:6225.00%
ROA:10.03%
PB:-68.79
PE(LYR):109.77

Loading ...

AbbVie, Other Healthcare Stocks Rise as Trump Administration Reportedly Targets Hospital Drug Markups

MT Newswires Live
·
Jul 03

Movement Alert|AbbVie Rises 3.01% in Regular Trading, Multiple Product Approvals and Positive Clinical Data Continue to Drive Momentum

Market Focus
·
Jul 02

Regenxbio Shares Rise on $100M Milestone Payment After First Patient Dosed in Eye-disease Trial

Dow Jones
·
Jul 02

Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says

MT Newswires Live
·
Jul 01

US FDA Approves Orca Bio's Blood Cancer Therapy

Reuters
·
Jul 01

Therapeuticsmd Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 01

Abbvie Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 01

Halozyme Names David Ramsay President of Drug Delivery Unit

Reuters
·
Jul 01

Sector Update: Healthcare Stocks Decline Tuesday Afternoon

MT Newswires Live
·
Jul 01

Abbvie, Genmab Blood-cancer Drug Has Competitive Profile

Dow Jones
·
Jun 30

U.S. Stocks on the Move-aerovironment, Oklo

Reuters
·
Jun 30

Market Chatter: AbbVie, Merck Investigated by US House Committee Over Clinical Trials in China

MT Newswires Live
·
Jun 30

Merck Down 1.2%, Abbvie Down 1%

THOMSON REUTERS
·
Jun 30

Exclusive-u.s. House Committee Investigates Abbvie, Merck China Drug Trials to Determine if They Fueled China's Military Capabilities

THOMSON REUTERS
·
Jun 30

Exclusive-u.s. Lawmaker Letters Request Documents on Hundreds of Trials over About 10 Years, Including on Data Protection Processes

THOMSON REUTERS
·
Jun 30

Nxera Pharma Co Ltd - Nxera Pharma to Receive Us$10 Million Milestone Payment from Abbvie Under Collaboration Targeting Neurological Diseases

Reuters
·
Jun 30

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide

Reuters
·
Jun 30

Basilea Publishes Investor Presentation on Anti-infectives Strategy, Pipeline Focus

Reuters
·
Jun 30

Is AbbVie (ABBV) Fully Valued After New Rinvoq And Skyrizi Approvals?

Simply Wall St.
·
Jun 30

Abbvie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

THOMSON REUTERS
·
Jun 30